At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Interferon gamma-1bdrug
Likely dose
Interferon gamma-1b 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Jan 28, 2016·Updated Oct 22, 2024
In Brief
A Phase 2 clinical trial evaluating Interferon gamma-1b for Osteopetrosis. Completed, enrolled 5 participants across 2 sites.
Detailed Summary
This study evaluates the effects of ACTIMMUNE (IFN-γ1b) in children and adults with intermediate osteoporosis. All participants will receive treatment with ACTIMMUNE for 12 months. The investigators hypothesize that ACTIMMUNE will be tolerated by participants for the full 12 months and result in decreased disease severity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopetrosis
CountriesUnited States
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionMar 2019
Study CompletionApr 2019
TodayJul 2026
First PostedJan 28, 2016
Enrollment StartFeb 22, 2016
Primary CompletionMar 11, 2019
Study CompletionApr 11, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.4 years ago
Interventions
Interferon gamma-1bdrug
gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly